Synthesis and evaluation of the aldolase antibody-derived chemical-antibodies targeting α5β1 integrin

Molecular Pharmaceutics

Volumn 10, Issue 2, 2013, Pages 538-543

  Goswami, Rajib K ^a   Liu, Yuan ^a   Liu, Cheng ^a   Lerner, Richard A ^a   Sinha, Subhash C ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

aldolase antibody; cancer; chemical programming; chemical antibody (chem Ab); in situ convergent strategy; integrin 5 1

Indexed keywords

ENZYME ANTIBODY; FRUCTOSE BISPHOSPHATE ALDOLASE; INTEGRIN ALPHA 5 BETA 1 ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BINDING; DRUG BINDING SITE; DRUG CONJUGATION; DRUG EFFECT; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN TARGETING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; FRUCTOSE-BISPHOSPHATE ALDOLASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INTEGRIN ALPHA5BETA1;

EID: 84873382943     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp3004463     Document Type: Article

References (46)

1. Hynes, R. O. Integrins: bidirectional, allosteric signalling machines Cell 2002, 110, 673-687 (Pubitemid 35283958)
2. Hu, P.; Luo, B. H. Integrin bidirectional signaling across the plasma membrane J. Cell Physiol. 2012, 307-316
3. Berrier, A. L.; Yamada, K. M. Cell-matrix adhesion J. Cell Physiol. 2007, 213, 565-573 (Pubitemid 350058247)
4. Danen, E. H.; Sonnenberg, A. Integrins in regulation of tissue development and function J. Pathol. 2003, 201, 632-641
5. Avraamides, C. J.; Garmy-Susini, B.; Varner, J. A. Integrins in angiogenesis and lymphangiogenesis Nat. Rev. Cancer 2008, 8, 604-617
6. Caswell, P. T.; Vadrevu, S.; Norman, J. C. Integrins: masters and slaves of endocytic transport Nature Rev. Mol. Cell Biol. 2009, 10, 843-853
7. Chiodoni, C.; Colombo, M. P.; Sangaletti, S. Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis Cancer Metastasis Rev. 2010, 29, 295-307
8. Weis, S. M.; Cheresh, D. A. Tumor angiogenesis: molecular pathways and therapeutic targets Nat. Med. 2011, 17, 1359-1370
9. Yao, E. S.; Zhang, H.; Chen, Y.-Y.; Lee, B.; Chew, K.; Moore, D.; Park, C. Increased β1 integrin is associated with decreased survival in invasive breast cancer Cancer Res. 2007, 67, 659-664 (Pubitemid 46192205)
10. Han, S. W.; Roman, J. Extracellular matrix and aberrant signaling in lung carcinoma: role of fibronectin in the control of human lung carcinoma cell growth, apoptosis and resistance to therapy Curr. Signal Transduction Ther. 2007, 2, 1-10 (Pubitemid 46723174)
11. Nam, J.-M.; Onodera, Y.; Bissell, M. J.; Park, C. C. Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin α5β1 and fibronectin Cancer Res. 2010, 70, 5238-5248
12. Desgrosellier, J. S.; Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities Nature Rev. Cancer 2010, 10, 9-22
13. Cox, D.; Brennan, M.; Moran, N. Integrins as therapeutic targets: lessons and opportunities Nat. Rev. Drug Discovery 2010, 9, 804-820
14. Rader, C.; Sinha, S. C.; Popkov, M.; Lerner, R. A.; Barbas, C. F., III. A chemically programmed monoclonal antibody for cancer therapy Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 5396-5400
15. Guo, F.; Das, S.; Mueller, B. M.; Barbas, C. F., III; Lerner, R. A.; Sinha, S. C. Breaking the one antibody-one target axiom Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 11009-11014 (Pubitemid 44148409)
16. Wagner, J.; Lerner, R. A.; Barbas, C. F., III. Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes Science 1995, 270, 1797-1800 (Pubitemid 26007222)
17. Zhong, G.; Lerner, R. A.; Barbas, C. F., III. Broadening the aldolase catalytic antibody repertoire by combining reactive immunization and transition state theory: new enantio- and diastereoselectivities Angew. Chem., Int. Ed. 1999, 38, 3738-3741 (Pubitemid 30022002)
18. Li, L.-S.; Rader, C.; Matsushita, M.; Das, S.; Barbas, C. F., III; Lerner, R. A.; Sinha, S. C. Chemical-adaptor immunotherapy: design, synthesis and evaluation of novel integrin-targeting devices J. Med. Chem. 2004, 47, 5630-5640 (Pubitemid 39447260)
19. Rader, C.; Turner, J. M.; Heine, A.; Shabat, D.; Sinha, S. C.; Wilson, I. A.; Lerner, R. A.; Barbas, C. F., III. A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy J. Mol. Biol. 2003, 332, 889-899 (Pubitemid 37101375)
20. Goswami, R. K.; Huang, Z.-Z.; Forsyth, J. S.; Felding-Habermann, B.; Sinha, S. C. Multiple catalytic aldolase antibodies suitable for chemical programming Bioorg. Med. Chem. Lett. 2009, 19, 3821-3824
21. Goswami, R. K.; Bajjuri, K. M.; Forsyth, J. S.; Das, S.; Hassenpflug, W.; Huang, Z. Z.; Lerner, R. A.; Felding-Habermann, B.; Sinha, S. C. Chemically programmed antibodies targeting multiple alpha(V) integrins and their effects on tumor-related functions in vitro Bioconjugate Chem. 2011, 22, 1535-1544
22. Doppalapudi, V. R.; Tryder, N.; Li, L.; Aja, T.; Griffith, D.; Liao, F.-F.; Roxas, G.; Ramprasad, M. P.; Bradshaw, C.; Barbas, C. F., III. Chemically programmed antibodies: endothelin receptor targeting Covx-bodies Bioorg. Med. Chem. Lett. 2007, 17, 501-506 (Pubitemid 46073729)
23. Gavrilyuk, J. I.; Wuellner, U.; Salahuddin, S.; Goswami, R. K.; Sinha, S. C.; Barbas, C. F., III. An efficient chemical approach to bispecific antibodies and antibodies of high valency Bioorg. Med. Chem. Lett. 2009, 19, 3716-3720
24. Doppalapudi, V. R.; Huang, J.; Liu, D.; Jin, P.; Liu, B.; Li, L.; Desharnais, J.; Hagen, C.; Levin, N. J.; Shields, M. J.; Parish, M.; Murphy, R. E.; Rosario, J. D.; Oates, B. D.; Lai, J.-Y.; Matin, M. J.; Ainekulu, Z.; Bhat, A.; Bradshaw, C. W.; Woodnutt, G.; Lerner, R. A.; Lappe, R. W. Chemical generation of bispecific antibodies Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 22611-22616
25. Popkov, M.; Rader, C.; Gonzalez, B.; Sinha, S. C.; Barbas, C. F., III. Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector Int. J. Cancer 2006, 119, 1194-1207 (Pubitemid 44116929)
26. Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Click chemistry: diverse chemical function from a few good reactions Angew. Chem., Int. Ed. 2001, 40, 2004-2021
27. Stragies., R.; Osterkamp, F.; Zischinsky, G.; Vossmeyer, D.; Kalkhof, H.; Reimer, U.; Zahn, G. Design and synthesis of a new class of selective integrin α5β1 antagonists J. Med. Chem. 2007, 50, 3786-3794 (Pubitemid 47292042)
28. Delouvrié, B.; Al-Kadhimi, K.; Arnould, J. C.; Barry, S. T.; Cross, D. A.; Didelot, M.; Gavine, P. R.; Germain, H.; Harris, C. S.; Hughes, A. M.; Jude, D. A.; Kendrew, J.; Lambert-van der Brempt, C.; Lohmann, J. J.; Ménard, M.; Mortlock, A. A.; Pass, M.; Rooney, C.; Vautier, M.; Vincent, J. L.; Warin, N. Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting A5β1: Part 1 Bioorg. Med. Chem. Lett. 2012, 22, 4111-4116
29. Delouvrié, B.; Al-Kadhimi, K.; Arnould, J. C.; Barry, S. T.; Cross, D. A.; Didelot, M.; Gavine, P. R.; Germain, H.; Harris, C. S.; Hughes, A. M.; Jude, D. A.; Kendrew, J.; Lambert-van der Brempt, C.; Lohmann, J. J.; Ménard, M.; Mortlock, A. A.; Pass, M.; Rooney, C.; Vautier, M.; Vincent, J. L.; Warin, N. Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting A5β1: Part 2 Bioorg. Med. Chem. Lett. 2012, 22, 4117-4121
30. Tolomelli, A.; Gentilucci, L.; Mosconi, E.; Viola, A.; Dattoli, S. D.; Baiula, M.; Spampinato, S.; Belvisi, L.; Civera, M. Development of isoxazoline-containing peptidomimetics as dual αvβ3 and α5β1 integrin ligands ChemMedChem 2011, 6, 2264-2272
31. Friedlander, D. R.; Zagzag, D.; Shiff, B.; Cohen, H.; Allen, J. C.; Kelly, P. J.; Grume, M. Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves αv and β1 integrins Cancer Res. 1996, 56, 1939-1947
32. Himo, F.; Lovell, T.; Hilgraf, R.; Rostovtsev, V. V.; Noodleman, L.; Sharpless, K. B.; Fokin, V. V. Copper(I)-catalyzed synthesis of azoles. DFT study predicts unprecedented reactivity and intermediates J. Am. Chem. Soc. 2005, 127, 210-216 (Pubitemid 40094384)
33. CupriSorb is a synthetic adsorbent that removes copper in all its forms and is available from Seachem. http://www.seachem.com.
34. Hong, Vu.; Steinmetz, N. F.; Manchester, M.; Finn, M. G. Labeling live cells by copper-catalyzed alkyne-azide click chemistry Bioconj. Chem. 2010, 21, 1912-1916
35. Sinha, S. C.; Das, S.; Li, L.-S.; Lerner, R. A.; Barbas, C. F., III. Preparation of integrin alpha(v)beta(3)-targeting Ab 38C2 constructs Nature Prot. 2007, 2, 449-456 (Pubitemid 47040060)
36. Meyer., A.; Auernheimer, J.; Modlinger, A.; Kessler, H. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting Curr. Pharm. Des. 2006, 12, 2723-2747 (Pubitemid 44184633)
37. Maglott, A.; Bartik, P.; Cosgun, S.; Klotz, P.; Rondé, P.; Fuhrmann, G.; Takeda, K.; Martin, S.; Dontenwill, M. The small A5B1 integrin antagonist, SJ749, reduces proliferation and clonogenicity of human astrocytoma cells Cancer Res. 2006, 66, 6002-6007
38. Khalili, P.; Arakelian, A.; Chen, G.; Plunkett, M. L.; Beck, I.; Parry, G. C.; Donate, F.; Shaw, D. E.; Mazar, A. P.; Rabbani, S. A. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo Mol. Cancer Ther. 2006, 5, 2271-2280 (Pubitemid 44530464)
39. Sudhakar, A.; Sugimoto, H.; Yang, C.; Lively, J.; Zeisberg, M.; Kalluri, R Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 4766-4771 (Pubitemid 36457804)
40. Yi, M.; Ruoslahti, E. A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 620-624 (Pubitemid 32105092)
41. Bhaskar, V.; Fox, M.; Breinberg, D.; Wong, M. H.; Wales, P. E.; Rhodes, S.; DuBridge, R. B.; Ramakrishnan, V. Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits Invest. New Drugs 2008, 26, 7-12
42. Matsumura, T.; Wolff, K.; Petzelbauer, P. Endothelial cell tube formation depends on cadherin 5 and CD31 interactions with filamentous actin J. Immunol. 1997, 158, 3408-3416 (Pubitemid 127484061)
43. Reynolds, A. R.; Hart, I. R.; Watson, A. R.; Welti, J. C.; Silva, R. G.; Robinson, S. D.; Da Violante, G.; Gourlaouen, M.; Salih, M.; Jones, M. C.; Jones, D. T.; Saunders, G.; Kostourou, V.; Perron-Sierra, F.; Norman, J. C.; Tucker, G. C.; Hodivala-Dilke, K. M. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors Nature Med. 2009, 15, 392-400
44. Aslakson, C. J.; Miller, F. R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor Cancer Res. 1992, 52, 1399-1405
45. Sua, F.; Kozaka, K. R.; Imaizumib, S.; Gaoa, F.; Amneusa, M. W.; Grijalvab, V.; Nga, C.; Wagnerb, A.; Houghb, G.; Farias-Eisnerb, G.; Anantharamaiahc, G. M.; Van Lentenb, B. J.; Navabb, M.; Fogelmanb, A. M.; Reddy, S. T.; Farias-Eisnera, R. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 19997-20002
46. Zhu, X; Tanaka, F.; Lerner, R. A.; Barbas, C. F., III; Wilson, I. A. Direct observation of an enamine intermediate in amine catalysis J. Am. Chem. Soc. 2009, 131, 18206-18207